RxDoctor Payments Data

Maryam Sickinger, DO

Dermatology · Palm Desert, CANPI 1841514049

Payments from drug & device makers

$6,507in general payments, 2019–2025

Across 102 payments — averaging $63.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$2K
  • Biofrontera Inc.$804
  • Sun Pharmaceutical Industries Inc.$538
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$438
  • Sanofi$357
  • Dermavant Sciences, Inc.$306
  • plus $2K from 23 others

What the payments were for

  • Speaking & faculty fees$3505%
  • Food & beverage$6,15795%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,507 in reported general payments places this provider in the 70th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$1,293,490
Medicare patients
1,440
Services billed
23,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast19$91,019
Ketoconazole236$3,575
Betamethasone Dipropionate116$3,547
Doxycycline Hyclate119$1,889
ValacyclovirValacyclovir Hcl27$1,710
Clobetasol Propionate51$1,628
Triamcinolone Acetonide217$1,438
Permethrin34$982
Fluorouracil14$771
Tretinoin15$745
Metronidazole15$702
Clindamycin Phosphate11$443
Minoxidil39$443
Spironolactone14$333
Fluconazole29$225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$92$91,01919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,875 dermatology providers in California.

Other dermatology in Palm Desert

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →